PMID- 7691882
OWN - NLM
STAT- MEDLINE
DCOM- 19931112
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 92
IP  - 4
DP  - 1993 Oct
TI  - Effects of chronic treatment with the c-kit ligand, stem cell factor, on 
      immunoglobulin E-dependent anaphylaxis in mice. Genetically mast cell-deficient 
      Sl/Sld mice acquire anaphylactic responsiveness, but the congenic normal mice do 
      not exhibit augmented responses.
PG  - 1639-49
AB  - We treated genetically mast cell-deficient WCB6F1-Sl/Sld mice and the congenic 
      normal (WCB6F1(-)+/+) mice with the c-kit ligand recombinant rat stem cell 
      factor164 (rrSCF164; 100 micrograms/kg per d, subcutaneously) or with vehicle for 
      21 d, then passively sensitized the mice with anti-dinitrophenol30-40 
      immunoglobulin E (IgE) antibodies, and 1 d later measured the changes in heart 
      rate, pulmonary dynamic compliance, and pulmonary conductance, and assessed the 
      death rates associated with intravenous challenge of these animals with specific 
      antigen. rrSCF164 treatment induced the development of mast cells in Sl/Sld mice, 
      and these mice exhibited tachycardia, but not death, after challenge with IgE and 
      antigen. rrSCF164 treatment induced mast cell hyperplasia in +/+ mice, but the 
      cardiopulmonary changes associated with passive anaphylaxis in these mice were 
      virtually indistinguishable from those observed in control +/+ mice treated with 
      vehicle instead of rrSCF164. Moreover, the highest dose of antigen challenge 
      produced significantly fewer fatalities in rrSCF164-treated than in 
      vehicle-treated +/+ mice (1/11 vs. 8/11, respectively, P < 0.01). Thus, in normal 
      mice, chronic treatment with rrSCF164 induces mast cell hyperplasia but does not 
      increase, and in certain respects diminishes, the severity of IgE-dependent 
      anaphylactic reactions.
FAU - Ando, A
AU  - Ando A
AD  - Department of Pathology, Beth Israel Hospital, Boston, Massachusetts 02215.
FAU - Martin, T R
AU  - Martin TR
FAU - Galli, S J
AU  - Galli SJ
LA  - eng
GR  - AI-22674/AI/NIAID NIH HHS/United States
GR  - AI-23990/AI/NIAID NIH HHS/United States
GR  - AI-33372/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Hematopoietic Cell Growth Factors)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Serum Albumin)
RN  - 0 (Stem Cell Factor)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Anaphylaxis/*physiopathology
MH  - Animals
MH  - Heart Rate/drug effects/physiology
MH  - Hematopoietic Cell Growth Factors/*pharmacology
MH  - Humans
MH  - Immunoglobulin E/*immunology
MH  - Lung/drug effects/physiology/*physiopathology
MH  - Lung Compliance/drug effects/physiology
MH  - Male
MH  - Mast Cells/drug effects/*physiology
MH  - Mice
MH  - Mice, Mutant Strains
MH  - Organ Specificity
MH  - Rats
MH  - Recombinant Proteins/pharmacology
MH  - Serum Albumin/immunology
MH  - Stem Cell Factor
PMC - PMC288322
EDAT- 1993/10/01 00:00
MHDA- 1993/10/01 00:01
PMCR- 1993/10/01
CRDT- 1993/10/01 00:00
PHST- 1993/10/01 00:00 [pubmed]
PHST- 1993/10/01 00:01 [medline]
PHST- 1993/10/01 00:00 [entrez]
PHST- 1993/10/01 00:00 [pmc-release]
AID - 10.1172/JCI116749 [doi]
PST - ppublish
SO  - J Clin Invest. 1993 Oct;92(4):1639-49. doi: 10.1172/JCI116749.